From: Metabolic engineering of Lactobacilli spp. for disease treatment
Strains | Strategy | Expression mode | Mechanisms | Diseases | Treating effect | Experimental model | Reference |
---|---|---|---|---|---|---|---|
Secreting vaccines for treating virus infection | |||||||
L. plantarum NC8 | Co-expressing hemagglutinin (HA) with the dendritic cell-targeting peptide (DCpep) | Plasmid-based | Inducing avian influenza virus-specific cell-mediated and humoral immune responses | Against H9N2 AIV | Improving the survival rate of AIV-infected mouse and chicken models by inducing robust immune responses | Mice and chicken challenged with H9N2 virus | [57] |
L. casei ATCC 393 | Co-expressing CSFV-specific cytotoxic T lymphocyte (CTL) epitope 290 and the VP2 antigen of PPV | Plasmid-based | Increasing the mucosal and systemic immune responses | Against CSFV and PPV | This engineered strain showed 86.7% effective protection for the CSFV-challenged pig | Pig challenged with CSFV strain Shimen | [58] |
L. casei ATCC 393 | Secreting the VP2 protein of infectious pancreatic necrosis virus (IPNV) | Plasmid-based | Inducing local mucosal and systemic immune responses | Against IPNV | This recombinant strain induced more than 3-fold reduction in viral load compared to control group | Rainbow trout (Oncorhynchus mykiss) that intraperitoneally injected with IPNV | [59] |
Secreting vaccine for treating parasite infection | |||||||
L. casei Zhang | Expressing immunodominant surface protein P23 of C. parvum sporozoites | Plasmid-based | Inducing mucosal immune system to elicit serum immunoglobulin G (IgG) and mucosal IgA | Against C. parvum | Increasing the secretion of immunity factors such as IgA, IL6, and IFN-γ | BALB/c mice | [60] |
Secreting vaccines for treating pathogens infection | |||||||
L. casei ATCC 393 | Expressing F4 (K88) fimbrial adhesin FaeG | Plasmid-based | Inducing effective fimbriae-specific mucosal and systemic immune responses | Against enterotoxigenic Escherichia coli (ETEC) infection | Using LTAK63 and LTB as oral adjuvant, this engineered strain exhibited 100% protection against ETEC challenge and developed mild diarrhea for 2–3 days | SPF BALB/c mice challenged with F4 + ETEC strain CVCC 230 | [61] |
L. acidophilus NCFM | Secreting the protective antigen (PA) of B. anthracis that genetically fused to a DC-binding peptide (DCpep) | Plasmid-based | Inducing PA-neutralizing antibody and T-cell mediated immune responses | Against B. anthracis infection | Increasing the survival rate of B. anthracis-infected mice from 0–100% | A/J mice challenged with B. anthracis Sterne pXO1+/pXO2− | [62] |
L. reuteri 3630 and 3632 | Secreting the nanobodies against NetB and α toxin of C. perfringens | Plasmid-based | Neutralizing NetB and α toxin of C. perfringens | Against necrotic enteritis | Protecting the chickens from necrotic enteritis-associated mortality (1.7- to 2.6-fold reduction) and reducing the pathological scores by 2.5- to 3.6-fold | Chickens challenged with Eimeria maxima and C. perfringens | [63] |
Secreting vaccines for treating neurodegeneration disease | |||||||
L. lactis subsp. cremoris MG1363 | Expressing human p62 protein | Plasmid-based | Improving memory function, modulating of neuronal proteolysis, and decreasing AD typical signs | Against Alzheimer’s disease (AD) | The Aβ(1–42) peptide level was decreased by 42%; The activities of proteasome T-L and branched-chain amino acid preferring (BrAAP) were inhibited by 70% and 50%, respectively; The levels of protein oxidation products (3-NT and carbocyanine) were decreased by 1.37- to 1.78-fold; The levels of lipid peroxidation product (4-HNE) was decreased by 65%; The expression of anti-inflammatory cytokine (IL-10) was upregulated by 3-fold; The expression of pro-inflammatory cytokines (e.g., INF-γ, IL-1β, TNF-α, IL-2) were decreased by 2.0- to 3.25-fold | Triple transgenic mice 3xTg-AD | [65] |
Secreting allergens for treating allergy | |||||||
L. plantarum NCIMB8826 Int-1 | Secreting the major birch pollen allergen Bet v 1 | Plasmid-based | Decreasing allergen-specific IgE and increasing allergen-specific IgA at the mucosae | Against birch pollen allergy | This engineered strain could activate the Th1-type immune responses effectively in mice and reduce the production of IL-5 significantly | Aerosol challenges with a 1% birch pollen solution in female BALB/c mice | [66] |
L. plantarum NCL21 | Secreting the Japanese cedar pollen allergen Cry j 1 (Cry j 1-LAB) | Plasmid-based | Suppressing the allergen-specific IgE response and nasal symptoms | Against cedar pollinosis | Bringing 2-fold reduction for the allergen-specific IgE response | Female BALB/c mice immunized with Cry j 1/alum | [67] |
Secreting antibodies | |||||||
L. paracasei | Secreting the 3D8 single-chain variable fragment (scFv) | Plasmid-based | Hydrolyzing the nucleic acids of virus | Against avian influenza virus (AIV) | Decreasing virus shedding to protect the chickens from H9N2 infection | SPF chickens challenged with AIV | [68] |
L. paracasei BL23 | Secretion and surface display of TcdB-neutralizing antibody | Plasmid-based | Neutralizing the cytotoxic effect of the toxin B | Against C. difficile | Improving the survival rate of C. difficile spore-challenged hamsters from 0–50% | Hamsters challenged with spores of a TcdA−TcdB+ strain of C. difficile | [69] |
Secreting pharmaceutical compounds | |||||||
L. johnsonii FI9785 | Exportation of bacteriophage endolysin CP25L | Plasmid-based | Lysing C. perfringens | Against C. perfringens | 2- to 2.6-log less C. perfringens was observed in the coculture experiment | Â | [70] |
L. Reuteri 6475 | Secreting murine interleukin-22 (IL-22) | Plasmid-based | Modulating the cytokines level in the serum and intestine | Against total body irradiation (TBI) | The survival rate of irradiation-treated mice was improved from 10–60% at day 30 | C57BL/6NTac mice irradiated to 8.75 and 9.25 Gy | [71] |
L reuteri 6475 | Secreting murine interleukin-22 (IL-22) | Plasmid-based | Reducing the liver weight and triglycerides | Against fatty liver disease | 22.3% decrease for liver weight ratio; 4.6-fold decrease for liver triglyceride | Male C57BL/6J mice with high-fat diet-induced obesity | [72] |
L. reuteri 6475 | Secreting murine interleukin-22 (IL-22) | Plasmid-based | Irradiation protection | Against alcoholic liver disease (ALD) | Increasing the expression level of Reg3g in small intestine, decreasing the level of Cxcl1 and Cxcl2 mRNAs, and reducing the bacteria translocation to liver | C57BL/6 mice with chronic and binge alcohol feeding (NIAAA) | [73] |
L. plantarum NC8 | Expressing angiotensin converting enzyme inhibitory peptide (ACEIPs) | Plasmid-based | Inhibiting angiotensin-converting enzyme (ACE) | Against hypertension | The SBP was decreased from 184.810 ± 4.305 mmHg to 167.111 ± 3.418 mmHg at day 15; The serum triglyceride was decreased from 1.213 ± 0.176 mM to 0.750 ± 0.181 mM | The spontaneously hypertensive rats (SHR) | [74] |
L. reuteri 647 | Secreting the Kv1.3 potassium blocker ShK-235 | Plasmid-based | Blocking the Kv1.3 currents | Against rheumatoid arthritis | Reducing the mean score of arthritis from 25 ± 2 to 4 ± 1(84% reduction) | Rat model of rheumatoid arthritis | [75] |
Secreting functional enzymes | |||||||
L. plantarum WCFS1 | Secreting the hydrolase domain of glycoside hydrolase PelA (PelAh) from P. aeruginosa | Plasmid-based | Degrading the biofilm of P. aeruginosa | Against P. aeruginosa | The cultures and supernatants of this engineered strain exhibited 80% and 85% reduction in biofilm biomass of P. aeruginosa | Â | [76] |
L. paracasei F19 | Expressing human N-acylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD) | Plasmid-based | Anti-inflammation | Against ulcerative colitis (UC) | Decreasing the DAI score (71% reduction), spleen weight (62% reduction), colitis histopathological score (47% reduction), MPO activity (56% reduction), the colonic level of iNOS (80% reduction), COX-2 (75% reduction) and IL-1β (63% reduction), the plasma level of NO (79% reduction), PGE2 (74% reduction), IL-1β (81% reduction) and TNF-α (86% reduction); Increasing the colon length (1.13-fold increment) and colonic expression of zonula occludens (ZO-1) (5.43-fold increment) and occluding (3.97-fold increment) | DSS-induced colitis mouse model | [77] |
L. paracasei ATCC 27092 | Secreting angiotensin converting enzyme 2 (ACE2) that fused with the non-toxic subunit B of cholera toxin | Plasmid-based | Reducing inflammation and oxidative stress by degrading Angiotensin II | Against diabetic retinopathy | Reducing the number of acellular capillaries, blocking the 20% retinal ganglion cell loss, and decreasing the expression of retinal inflammatory cytokines | STZ-induced diabetic eNOS−/− mice and Akita mice | [78] |
L. plantarum WCFS1 | Secreting oxalate decarboxylase (OxdC) | Plasmid-based | Increased intestinal oxalate degradation | Against hyperoxaluria | Reducing serum uric acid (34% reduction), urinary oxalate excretion (40% reduction) and CaOx crystal deposition | Male wistar albino rats with hyperoxaluria | [79] |
L. reuteri 100–23 C | Expressing phenylalanine lyase | Plasmid-based | Decreasing blood Phe concentrations | Against phenylketonuria (PKU) |  | PHAenu2 mouse model of PKU | [80] |
L. plantarum CM_PUJ411 | Secreting the human phenylalanine hydroxylase (PAH) | Plasmid-based | Secreting PAH to transport through the cell monolayer of Caco-2 cells and decrease phenylalanine (Phe) | Against phenylketonuria (PKU) | Decreasing the Phe levels (28% reduction) | Caco-2 cells | [81] |